The brain shrinkage observed in Alzheimer’s may be prevented by semaglutide, the drug in Ozempic
ZEPHYR/Science Photo Library/Alamy
Ozempic and Wegovy are already transforming how we treat type 2 diabetes and obesity, and from next year another condition affecting millions of people worldwide might be added to the list: Alzheimer’s disease.
Two clinical trials investigating semaglutide, the drug in Ozempic and Wegovy, as a therapy for early Alzheimer’s are expected to conclude in 2025. If the results are positive, it could mark a breakthrough in treating this intractable condition.
Thinkia is a professional platform where we provide informative content like current world news, all types of educational content, health awareness, food awareness, travel awareness, ideas and tips. We hope you like all the content provided by us.
